Abbvie Inc Stock Price, News & Analysis

Allergan Aesthetics (NYSE:ABBV) has launched its Faces of Natrelle® campaign, featuring nine women sharing their personal experiences with breast augmentation and reconstruction using Natrelle® breast implants. The campaign, selected through a nationwide casting call, includes diverse stories from breast cancer survivors, mothers, and professionals who chose breast procedures for various personal reasons.

The initiative aims to increase transparency and understanding around breast procedures, which remain among the most popular cosmetic and reconstructive surgeries in the U.S. Natrelle® offers 300 options with five profiles and three gel types for customized results. The campaign will be featured across social media channels and digital platforms, showcasing real stories of transformation and empowerment.

AbbVie (NYSE:ABBV) reported strong Q2 2025 financial results with net revenues of $15.423 billion, up 6.6% year-over-year. The company's immunology portfolio led growth with $7.631 billion in revenues, driven by Skyrizi ($4.423B) and Rinvoq ($2.028B). Neuroscience portfolio revenues grew 24.2% to $2.683 billion.

Key highlights include FDA approval for Rinvoq in giant cell arteritis and Emrelis for non-small cell lung cancer. The company raised its 2025 adjusted EPS guidance to $11.88-$12.08 from $11.67-$11.87, despite a $0.55 per share impact from IPR&D expenses.

Q2 adjusted diluted EPS increased 12.1% to $2.97, while GAAP EPS decreased 32.5% to $0.52, impacted by $0.42 per share from IPR&D expenses.

AbbVie (NYSE:ABBV) announced positive topline results from Study 2 of its Phase 3 UP-AA clinical trial evaluating upadacitinib (RINVOQ®) for severe alopecia areata treatment. The trial achieved its primary endpoint with 44.6% and 54.3% of patients treated with upadacitinib 15mg and 30mg respectively achieving ≥80% scalp hair coverage at week 24, compared to 3.4% for placebo.

Key secondary endpoints were also met, with 36.0% and 47.1% of patients reaching ≥90% scalp coverage in the respective dosage groups. The safety profile aligned with approved indications, with treatment-emergent serious adverse events occurring in 1.4% (15mg) and 2.8% (30mg) of patients. Common side effects included acne, nasopharyngitis, and upper respiratory tract infection. Results from Study 1 are expected in Q3 2025.

AbbVie (NYSE:ABBV) has submitted a supplemental New Drug Application (sNDA) to the FDA for a novel combination therapy using VENCLEXTA® (venetoclax) and acalabrutinib to treat previously untreated Chronic Lymphocytic Leukemia (CLL) patients.

The submission is supported by the Phase 3 AMPLIFY trial, which demonstrated statistically significant improvement in progression-free survival compared to standard chemoimmunotherapy. If approved, this would be the first all-oral, fixed-duration combination regimen of these drugs for CLL treatment, offering patients the potential benefit of treatment-free periods.

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the 2025 class for The Confidence Project, an initiative led by BOTOX® Cosmetic to support women entrepreneurs. The program includes a Virtual Community Summit, followed by a 12-week intensive "Boostcamp" powered by Hello Alice.

Selected entrepreneurs will receive business development coaching, mentorship, and community support. Following the Boostcamp, participants will compete in a Pitch Lab, where 20 business owners will be selected to receive $20,000 grants each from BOTOX® Cosmetic. The grant recipients will be announced in October 2025.

AbbVie (NYSE: ABBV) has entered into an exclusive licensing agreement with IGI Therapeutics SA for ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.

Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, plus tiered, double-digit royalties on net sales.

ISB 2001 was developed using IGI's proprietary BEAT® protein platform and represents a new frontier in immuno-oncology by engaging multiple targets simultaneously.

AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition centers on Capstan's lead asset CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy currently in Phase 1 clinical trials for B cell-mediated autoimmune diseases.

CPTX2309 delivers mRNA encoding an anti-CD19 chimeric antigen receptor to CD8-expressing cytotoxic T cells in vivo, offering a novel approach to treating autoimmune conditions. The therapy aims to deplete autoreactive antibody-producing pathogenic memory B cells and achieve immune system reset without requiring lymphodepletion preconditioning or complex ex vivo manufacturing.

The acquisition also includes Capstan's proprietary tLNP platform technology designed for RNA payload delivery. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act requirements.

AbbVie (NYSE:ABBV) announced that the FDA has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines and improve neck appearance. The product is currently approved in the U.S. for improving cheek skin smoothness in adults over 21.

The application is supported by a successful clinical study where 80% of patients achieved at least a 1-grade improvement in horizontal neck lines at month 1, and nearly 90% reported improvement in neck appearance. Treatment-emergent adverse events were mild and consistent with the known safety profile.

If approved, SKINVIVE by JUVÉDERM® would become the first hyaluronic acid injectable treatment specifically targeting neck lines, addressing a significant market need as neck appearance is a top concern among aesthetic treatment seekers.

AbbVie (NYSE: ABBV) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 31, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time. Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com, with an archived version available later that day.